Mylan

Mylan N.V. was a global generic and specialty pharmaceutical company. In November 2020, Mylan merged with Upzone, Pfizer’s off-patent medicine division, to form Vitris. Previously, the company was domiciled in the Netherlands, with the main executive office in Hatfield, Hertfordshire, UK and a “global centre” in Canonsburg, Pennsylvania, US.

In 2007, the company acquired India-based Matrix Laboratories Limited, a leading producer of active pharmaceutical ingredients (APIs) for generic drugs,[3] and a controlling interest in the generics business of Germany-based Merck KGaA. With this acquisition, the company grew from the third largest generic and pharmaceuticals company in the United States to the second largest generic and specialty pharmaceuticals company in the world.

Mylan went public on the OTC market in February 1973. It was listed on the NASDAQ and its shares were a component of the NASDAQ Biotechnology and S&P 500 indices.

The company was founded in 1961 and develops and manufactures drugs for a wide range of medical disciplines including oncology, anaphylaxis, antiretroviral, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious diseases, gastroenterology, diabetology, gynecology/endocrinology. Healthcare

Founded in 1961, the company was originally located in an abandoned skating rink in White Sulfur Springs, West Virginia. The facility moved to Pennsauken, New Jersey in 1962, to Princeton, West Virginia in 1963, and then to Morgantown, West Virginia in 1965, and in 1976 it moved its corporate headquarters to Canonsburg, Pennsylvania, a suburb of Pittsburgh. It eventually moved in 2004 to a new office center in nearby Southpointe, a suburban business park located in the Pittsburgh suburb of Cecil Township.

Milan Pharmaceuticals was founded in 1961 by Milan Puskar and Don Panoz as a drug distributor. In 1966, the company began manufacturing penicillin G tablets as well as vitamins and other dietary supplements.

Panoz left the company in 1969 and Puskar left the company in 1973, as it grew and faced financial difficulties. The board appointed Roy McKnight as chairman of the board, who persuaded Pushkar to return in 1976.

The company ceased operations as a contract manufacturing company in 1980 and instead chose to market their products under their own “Mylan-labeled” brand.

Share This Post

Recent Articles

© 2024 Pharmaceuticals Index. All rights reserved.